tiprankstipranks
California Nanotechnologies Corp (TSE:CNO)
:CNO
Canadian Market

California Nanotechnologies (CNO) AI Stock Analysis

Compare
27 Followers

Top Page

TSE:CNO

California Nanotechnologies

(CNO)

Select Model
Select Model
Select Model
Neutral 42 (OpenAI - 5.2)
Rating:42Neutral
Price Target:
C$0.25
▼(-25.29% Downside)
Action:ReiteratedDate:02/01/26
The score is held down primarily by weak recent financial performance (declining revenue, losses, higher leverage, and negative free cash flow). Technicals are also bearish with the stock below major moving averages, partially offset by oversold momentum readings. Valuation offers limited support because the negative P/E reflects ongoing losses and there is no dividend yield.
Positive Factors
Specialized manufacturing & process-development capability
CNO’s core business of nanostructured and specialty metal powders with scale-up and engineering services creates high technical barriers and customer stickiness. This fosters multi-year project work, repeat engineering engagements and structural revenue when industrial programs scale to production.
Negative Factors
Significant recent revenue decline
A ~32% TTM revenue drop materially erodes scale and makes fixed-cost absorption harder for a small producer. Sustained top-line weakness threatens long-term contracts, discourages capacity investment, and increases volatility in margins and cash generation across business cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized manufacturing & process-development capability
CNO’s core business of nanostructured and specialty metal powders with scale-up and engineering services creates high technical barriers and customer stickiness. This fosters multi-year project work, repeat engineering engagements and structural revenue when industrial programs scale to production.
Read all positive factors

California Nanotechnologies (CNO) vs. iShares MSCI Canada ETF (EWC)

California Nanotechnologies Business Overview & Revenue Model

Company Description
California Nanotechnologies Corp. engages in the research, development, and production of nanocrystalline materials through grain size reduction. The company provides spark plasma/ field assisted sintering (SPS/FAST); hot pressing; sintering; diff...
How the Company Makes Money
null...

California Nanotechnologies Financial Statement Overview

Summary
Financial results are under pressure in the TTM period: revenue declined sharply (~31.8%), profitability turned deeply negative, leverage is elevated (debt-to-equity ~1.15), and free cash flow is negative. While prior annual results showed stronger margins and positive cash flow, the latest trajectory indicates higher execution and liquidity risk.
Income Statement
28
Negative
Balance Sheet
38
Negative
Cash Flow
24
Negative
BreakdownTTMMay 2024May 2022May 2021May 2020Feb 2019
Income Statement
Total Revenue3.04M3.34M1.82M1.06M1.10M981.04K
Gross Profit1.22M2.33M669.57K439.97K523.36K482.77K
EBITDA-312.20K753.02K337.91K10.77K141.12K181.11K
Net Income-2.15M381.68K79.76K-161.40K-74.36K-77.42K
Balance Sheet
Total Assets4.11M2.36M1.41M587.40K864.54K1.02M
Cash, Cash Equivalents and Short-Term Investments340.66K841.35K294.13K25.29K56.31K24.45K
Total Debt2.46M1.21M1.94M1.94M2.31M2.31M
Total Liabilities1.98M2.21M2.70M2.24M2.47M2.56M
Stockholders Equity2.13M145.97K-1.29M-1.66M-1.61M-1.54M
Cash Flow
Free Cash Flow-129.01K89.98K604.26K33.20K180.62K95.44K
Operating Cash Flow-9.28K104.28K717.01K33.20K180.62K122.23K
Investing Cash Flow-111.05K-14.30K-112.75K0.000.00-26.78K
Financing Cash Flow85.84K535.33K-387.83K-62.52K-149.61K-118.51K

California Nanotechnologies Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.34
Price Trends
50DMA
0.32
Negative
100DMA
0.33
Negative
200DMA
0.39
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
47.14
Neutral
STOCH
45.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CNO, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.32, and below the 200-day MA of 0.39, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.14 is Neutral, neither overbought nor oversold. The STOCH value of 45.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CNO.

California Nanotechnologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
C$187.06M-10.46-6.96%3.12%5.06%93.02%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
44
Neutral
C$241.43M-3.44-414.40%6.29%-3.71%
42
Neutral
C$13.88M-2.61-86.94%-15.84%-375.96%
42
Neutral
C$107.61M-4.53-64.75%56.03%
41
Neutral
C$9.83M-6.5491.27%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:CNO
California Nanotechnologies
0.29
-0.67
-69.79%
TSE:BOS
Airboss of America
6.89
3.21
87.08%
TSE:NANO
Nano One Materials
0.90
0.21
30.43%
TSE:GMG
Graphene Manufacturing Group Ltd
2.05
1.37
201.47%
TSE:SURE
SureNano Science Ltd
0.29
0.21
262.50%

California Nanotechnologies Corporate Events

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
California Nanotechnologies Raises $935,900 in Non-Brokered Private Placement
Positive
Mar 24, 2026
California Nanotechnologies has closed a non-brokered private placement, issuing 3,119,666 units at CA$0.30 each for gross proceeds of about $935,900, with each unit including a common share and a warrant exercisable at US$0.30 for 18 months. The ...
Business Operations and StrategyPrivate Placements and Financing
California Nanotechnologies Launches Private Placement to Bolster Working Capital
Positive
Feb 24, 2026
California Nanotechnologies plans to raise up to CA$750,000 through a non-brokered private placement of 2,500,000 units priced at CA$0.30, each comprising one common share and one warrant exercisable at US$0.30 for 18 months. The company has also ...
Business Operations and StrategyFinancial Disclosures
California Nanotechnologies Hit by Revenue Slump but Sees Q4 Rebound and Defense, Nuclear Growth
Negative
Jan 29, 2026
California Nanotechnologies reported a sharp downturn in its third quarter of fiscal 2026, with revenues falling 78% year over year to US$392,481 and swinging to a net loss of US$1.09 million, largely due to delayed manufacturing service revenues,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 01, 2026